iPierian's Acquisition

iPierian was acquired by Bristol-Myers Squibb on April 29, 2014.

iPierian is a biotechnology company developing therapies for neurodegenerative disease, specifically focused on discovering monoclonal antibodies against targets of the Tau protein for treatment of Al…

Articles about iPierian's Acquisition: